Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) have identified a specific population of gamma delta T cells capable of detecting and destroying small cell lung cancer (SCLC) cells. Published in the journal Cancer Cell, the findings offer a potential new route for treating a disease that has historically evaded conventional immunotherapy due to its ability to mask itself from the immune system, ScienceAlert reported.
Gamma Delta T Cells Target Cancer Disguises
Small cell lung cancer remains one of the most aggressive forms of the disease, with survival rates for patients remaining below 7 percent five years after diagnosis. While immunotherapy has transformed treatment for other cancer types, it has struggled against SCLC because the tumors frequently slip past standard immune cells.
According to molecular biologist Kate Sutherland of WEHI, gamma delta T cells possess the ability to "see through" the camouflage used by these tumors. Laboratory tests conducted by the team, which involved building miniature tumors from patient-donated tissue samples, showed that these immune cells were highly effective at identifying and killing cancer cells that would otherwise remain hidden.
Combined Drug Therapy Enhances Immune Response
The research team found that the cancer-killing efficacy of gamma delta T cells increased significantly when paired with existing medications. Specifically, the study highlighted the use of tarlatamab, an approved lung cancer drug that helps bring immune cells into closer physical contact with their targets, and zoledronate, a medication currently used for bone problems.
Data from the IMpower133 and CASPIAN clinical trials provided the initial evidence for this approach. Researchers observed that patients whose tumors contained higher concentrations of gamma delta T cells generally experienced better outcomes. Zoledronate was shown in the lab to both increase the number of these immune cells and sharpen their ability to find tumors.
Future Clinical Translation Potential
The researchers are now working with the Doherty Institute to determine how these findings can be translated into clinical practice. Dr. Jin Ng of WEHI noted that the discovery supports the potential for "adoptive cell transfer," a process where a patient’s own immune cells are collected, multiplied outside the body, and reinfused to strengthen the immune system's attack on the cancer.
While development of these therapies is ongoing, the team is working toward a new class of immunotherapy drugs for small cell lung cancer.
Common Questions About SCLC Research
Why is small cell lung cancer so difficult to treat?
The disease is notoriously aggressive and excels at hiding from the immune system, which allows tumors to continue growing even when the body is on alert. Conventional immunotherapy, which relies on standard immune cells, has historically struggled to recognize these tumors.
What role does zoledronate play in this research?
Zoledronate, a drug already approved for bone-related conditions, was found to increase the quantity of gamma delta T cells in lab tests. It also helps these cells sharpen their ability to find tumors.
What is the next step for this therapy?
The WEHI team is working with the Doherty Institute to move the findings toward a new class of immunotherapy drugs.
Worth a look